Associate Professor of Medicine
Campus mail
101 Hanes House, Trent Drive, Durham, NC 27710
Phone
(919) 681-5961
Email address
lake.morrison@duke.edu
Education and Training
- Fellow in Pulmonary Medicine, Medicine, University of Pennsylvania, 2001 - 2004
- Medical Resident, Medicine, University of Pennsylvania, 1998 - 2001
- M.D., University of Pennsylvania, 1998
Grants
- AZ ORIN1001-002 D4325C00001: Phase 1b Double-Blind, Placebo-Controlled, Ascending Dose Trial: ORIN1001 in Subjects with Idiopathic Pulmonary Fibrosis
- WA42294 PRM-151: A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE LONG-TERM SAFETY AND EFFICACY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)
- WA42293 PRM-151-303: A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
- Novartis VAY736: A subject, investigator, and sponsor blinded randomized placebo controlled multicenter study to investigate VAY736 in patients with idiopathic pulmonary fibrosis
- GLPG1690-CL-304 A Phase 3 randomized double blind parallel group, placebo controlled multicenter study to evaluate efficacy and safety of 2 doses of GLPG1690 in addition to local standard of care
- BI 1199.248 INBUILD-ON An open label extension trial of the long term safety of nintedanib in patients with progressive fibrosing interstitial lung disease.
- Pulmonary Fibrosis Foundation Biomarker and/or Patient Registry Protocols
- Idiopathic Pulmonary Fibrosis Prespective Outcomes (IPF-PRO) Registry
- Evaluate Efficacy and Safety of CC-90001 in Subjects with Idiopathic Pulmonary Fibrosis